The Sequenom Center for Molecular Medicine (Sequenom CMM), a subsidiary of Sequenom Inc, San Diego, has completed the validation of an additional lab location in Raleigh-Durham, NC, and is now processing patient samples commercially.
This new lab location adds capacity and redundancy to the existing Sequenom CMM laboratory locations in California and Michigan.
With an initial capacity of 100,000 tests per year, the North Carolina facility will primarily support processing of the MaterniT21 PLUS laboratory-developed test (LDT) and will immediately increase Sequenom CMM’s total MaterniT21 PLUS testing capacity to more than 300,000 test samples per year.
This prenatal LDT analyzes the relative amount of chromosome 21, 18, and 13, as well as X and Y material in cell-free fetal DNA obtained from a maternal blood sample as early as 10 weeks of pregnancy.
The newfacility received its Clinical Laboratory Improvement Amendments (CLIA) registration for operation in May.
[Source: Sequenom]
